Navigation Links
Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Date:12/1/2009

NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

http://www.reportlinker.com/p0166816/The-Future-of-Monoclonal-Antibodies---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html

Summary

The author has released its latest research "The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global monoclonal antibodies market. The report analyzes the markets for monoclonal antibodies in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, annual cost of therapy and market potential are forecast until 2015 for select segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the monoclonal antibodies market from 2000 to 2008, forecast forward to 2015

- Analysis of the potential for the monoclonal antibodies market in select therapeutic areas. These include HER2 breast cancer, bone metastases, multiple sclerosis, Non Small Cell Lung cancer (NSCLC) and Rheumatoid Arthritis

- Market characterization of the monoclonal antibodies market including market size, annual cost of therapy, sales volume and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co, Biogen Idec, AstraZeneca, Bristol -Myers Squibb, Elan Pharmaceuticals, Amgen Inc and Eli Lilly

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global monoclonal antibodies market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 10

2 Global Monoclonal Antibodies Market: Introduction 12

2.1 GBI Research Report Guidance 13

3 Global Monoclonal Antibodies Market: Market Characterization 14

3.1 Introduction 14

3.2 Revenue Forecasts for the Global MAbs Market Potential 14

3.2.1 MAbs Treatment Potential 14

3.2.2 Drug Prices 16

3.2.3 Market Potential 17

3.2.4 Market Potential Segmentation 18

3.3 Revenue Forecasts of Global MAbs Market - Actual Market 19

3.3.1 MAbs Actual Treatment Population 19

3.3.2 Actual Sales 20

3.3.3 Actual Sales Segmentation 21

3.4 Treatment Usage Patterns 23

3.5 Global MAbs Trends 24

3.5.1 Market Trends 24

3.5.2 Technology Trends 25

3.6 Product Trends 25

3.6.1 Research and Development Focus Shifted Towards Humanized and Fully Humanized MAbs 25

3.7 Global MAbs Market Drivers 26

3.7.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth 26

3.7.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy 26

3.7.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs 26

3.7.4 Expanded Indications Opens up New Potential Patient Group 27

3.7.5 Lack of Generics Augmented the Sales Growth of MAbs 27

3.8 Global MAbs Market Restraints 27

3.8.1 High Cost of MAbs Hampering the Growth of Treatment Population 27

3.8.2 Adverse Effects - Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy 27

3.8.3 Industry Challenges - Majority of MAbs Receive Approvals as Last Option Therapies 28

3.9 Unmet Needs 28

3.9.1 The High Cost of MAb Therapies is the Major Unmet Need and it is Also Responsible for Low Utilization by Patients 28

3.9.2 MAbs Do Not Cure the Disease; They either Treat Signs and Symptoms or Decelerate Cell Proliferation 28

4 Global MAbs Market Potential: Therapeutic Distribution 29

4.1 MAbs Market Potential in HER2 Breast Cancer (Adjuvant and Metastatic) 29

4.1.1 Introduction 29

4.1.2 Prescription Population 31

4.1.3 Annual Cost of Therapy 32

4.1.4 Market Potential 33

4.2 MAbs Market Potential in Bone Metastases and Bone Loss Due to Cancer Therapy 34

4.2.1 Introduction 34

4.2.2 Prescription Population 35

4.2.3 Annual Cost of Therapy 36

4.2.4 Market Potential 37

4.3 MAbs Market Potential in Relapsing-remitting Multiple Sclerosis (RRMS) 38

4.3.1 Introduction 38

4.3.2 Prescription Population 40

4.3.3 Annual Cost of Therapy 41

4.3.4 Market Potential 42

4.4 MAbs Market Potential in Metastatic Non-Small Cell Lung Cancer (NSCLC) 43

4.4.1 Introduction 43

4.4.2 Prescription Population 45

4.4.3 Annual Cost of Therapy 45

4.4.4 Market Potential 46

4.5 MAbs Market Potential in Rheumatoid Arthritis 47

4.5.1 Introduction 47

4.5.2 Prescription Population 49

4.5.3 Annual Cost of Therapy 50

4.5.4 Market Potential 51

5 Global MAbs Market: Pipeline Analysis 53

5.1 Introduction 53

5.2 MAbs Nomenclature 53

5.3 Monoclonal Antibody Technology 54

5.4 Applications of MAbs 55

5.4.1 Detection Assays 55

5.4.2 Purification Techniques 55

5.4.3 Gene Identification 55

5.4.4 Applied Chemistry 55

5.4.5 Disease Therapy 56

5.5 Therapeutic Applications in Oncology 56

5.5.1 Introduction 56

5.5.2 Marketed Therapies 56

5.5.3 Therapies in Late Stage Pipeline 62

5.6 Therapeutic Applications in Autoimmune and Inflammatory Diseases 66

5.6.1 Introduction 66

5.6.2 Marketed Therapies 66

5.6.3 Therapies in Late Stage Pipeline 71

5.7 Therapeutic Applications in Respiratory Diseases 74

5.7.1 Introduction 74

5.7.2 Marketed Therapies 74

5.7.3 Therapies in Late Stage Pipeline 75

5.8 Therapeutic Applications in Infectious Diseases 75

5.8.1 Introduction 75

5.8.2 Marketed Therapies 76

5.8.3 Therapies in Pipeline 76

5.9 Therapeutic Applications in Organ Transplantation 77

5.9.1 Introduction 77

5.9.2 Marketed Therapies 78

5.10 Therapeutic Applications in Cardiovascular Diseases 79

5.10.1 Introduction 79

5.10.2 Marketed Therapies 80

5.10.3 Therapies in Pipeline 81

5.11 New Indications 81

5.11.1 Central Nervous System 82

5.11.2 Diabetes 83

5.12 Insights into Most Promising Drugs 83

5.12.1 Denosumab 83

6 Global MAbs Market: M&A Landscape 86

6.1 Overview 86

6.1.1 Emergent BioSolutions acquires Avanir Pharmaceuticals 86

6.1.2 MacroGenics acquires Raven Biotechnologies 86

6.1.3 Thermo Fisher acquires Affinity BioReagents 87

6.2 R&D Licensing Agreements 87

6.2.1 Deals by Phase 87

6.2.2 Deals by Geography 87

6.2.3 Deals by Licensing Type 88

6.2.4 Deals by Value ($) 88

6.2.5 Preclinical 89

6.2.6 Phase I 90

6.2.7 Phase II 91

6.2.8 Phase III 92

6.2.9 Approved 92

7 Global MAbs Market: Competitive Landscape 94

7.1 Evolving competitive landscape 94

7.1.1 Major players 94

7.1.2 Key MAbs in the Market 95

7.2 Company Benchmarking Analysis 96

7.3 Roche/Genentech 98

7.3.1 Key Monoclonal Antibody Drugs 100

7.3.2 Key Indications of Interest 102

7.3.3 Pipeline Analysis 103

7.4 Abbott 104

7.4.1 Key MAbs 105

7.4.2 Key Indications of Interests 106

7.4.3 Pipeline Analysis 106

7.5 Johnson & Johnson 106

7.5.1 Key MAbs 107

7.5.2 Key Indications of Interest 108

7.5.3 Pipeline Analysis 108

7.6 Biogen Idec. 109

7.6.1 Key MAbs 110

7.6.2 Key Indications of Interest 111

7.6.3 Pipeline Analysis 111

7.7 Merck/Schering Plough 112

7.7.1 Key MAbs 113

7.7.2 Key Indications of Interest 113

7.7.3 Pipeline Analysis 114

7.8 AstraZeneca 115

7.8.1 Key MAbs 115

7.8.2 Key Indications of Interest 116

7.8.3 Pipeline Analysis 116

7.9 Bristol-Myers Squibb 117

7.9.1 Key MAbs 118

7.9.2 Key Indications of Interest 118

7.10 Elan 119

7.10.1 Key MAbs 120

7.10.2 Key Indications of Interest 120

7.10.3 Pipeline Analysis 121

7.11 Eli Lilly 122

7.11.1 Key Monoclonal Antibody Drugs 123

7.11.2 Key Indications of Interests 123

7.11.3 Pipeline Analysis 124

7.12 Amgen 124

7.12.1 Key Monoclonal Antibody Drugs 125

7.12.2 Key Indications of Interest 126

7.12.3 Pipeline Analysis 127

8 Global MAbs Market: Appendix 128

8.1 Research Methodology 128

8.2 Geographical Scope 128

8.3 Coverage 128

8.4 Secondary Research 129

8.5 Primary Research 129

8.6 Forecasts 129

8.6.1 Epidemiology-based Forecasting 129

8.7 Expert Panel Validation 131

8.8 Contact Us 132

8.9 Disclaimer 132

1.1 List of Tables

Table 1: MAbs Market, Global, MAbs Treatment Potential, 2000-2008 15

Table 2: MAbs Market, Global, MAbs Treatment Potential, 2008-2015 15

Table 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2008 16

Table 4: MAbs Market, Global, Annual Cost of Therapy ($), 2008-2015 17

Table 5: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2008 18

Table 6: MAbs Market, Global, MAbs Market Potential ($ bn), 2008-2015 18

Table 7: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2008 20

Table 8: MAbs Market, Global, MAbs Actual Treatment Population, 2008-2015 20

Table 9: MAbs Market, Global, Actual Sales ($ bn), 2000-2008 21

Table 10: MAbs Market, Global, Actual Sales ($ bn), 2008-2015 21

Table 11: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2008 23

Table 12: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008-2015 23

Table 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2008 31

Table 14: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2008-2015 32

Table 15: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2008 32

Table 16: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2008-2015 32

Table 17: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2008 33

Table 18: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2008-2015 33

Table 19: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population,

2009-2015 36

Table 20: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015 37

Table 21: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn),

2009-2015 38

Table 22: MAbs Market, Global, RRMS, Treatment Options, 2008 40

Table 23: MAbs Market, Global, RRMS, Prescription Population, 2000-2008 41

Table 24: MAbs Market, Global, RRMS, Prescription Population, 2008-2015 41

Table 25: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2008 42

Table 26: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2008-2015 42

Table 27: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2008 42

Table 28: MAbs Market, Global, RRMS, Market Potential ($ bn), 2008-2015 43

Table 29: MAbs Market, Global, Metastatic NSCLC, Treatment Options, 2008 44

Table 30: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2008 45

Table 31: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2008-2015 45

Table 32: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2008 46

Table 33: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2008-2015 46

Table 34: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2008 47

Table 35: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2008-2015 47

Table 36: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2008 50

Table 37: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2008-2015 50

Table 38: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2008 51

Table 39: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2008-2015 51

Table 40: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2008 52

Table 41: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2008-2015 52

Table 42: MAbs Market, Global, Monoclonal Antibody Nomenclature 54

Table 43: MAbs Market, Global, Licensing Agreements for Drugs in the Preclinical Stage,

2008-2009 90

Table 44: MAbs Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009 91

Table 45: MAbs Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009 92

Table 46: MAbs Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009 92

Table 47: MAbs Market, Global, Licensing Agreements for Approved Drugs, 2008-2009 93

Table 48: MAbs Market, Global, Top 5 Companies Sales ($m), 2006-2008 95

Table 49: MAbs Market, Global, Top 10 MAbs ($m), 2006-2008 98

Table 50: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015 100

Table 51: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015 105

Table 52: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015 107

Table 53: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015 110

Table 54: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015 113

Table 55: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015 115

Table 56: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015 118

Table 57: MAbs Market, Global, Elan Revenues ($ m), 2006-2015 120

Table 58: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015 122

Table 59: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015 125

1.2 List of Figures

Figure 1: MAbs Market, Global, Major Factors Influencing the Global MAbs Market, 2008 14

Figure 2: MAbs Market, Global, MAbs Treatment Potential, 2000-15 15

Figure 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2015 16

Figure 4: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2015 17

Figure 5: MAbs Market, Global, Market Segmentation by Disease, 2008 and 2015 19

Figure 6: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2015 20

Figure 7: MAbs Market, Global, Actual Sales ($ bn), 2000-2015 21

Figure 8: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008 and 2015 22

Figure 9: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2015 23

Figure 10: MAbs Market, Global, Treatment Population Trends, 2000-2015 24

Figure 11: MAbs Market, Global, MAbs Segmented by Origin, 1992-2009 25

Figure 12: MAbs Market, Global, Market Share of Key Indications, 2008 29

Figure 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2015 31

Figure 14: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2015 32

Figure 15: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2015 33

Figure 16: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population, 2009-2015 36

Figure 17: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015 37

Figure 18: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn), 2009-2015 38

Figure 19: MAbs Market, Global, Multiple Sclerosis, Diseased Population, 2008 39

Figure 20: MAbs Market, Global, RRMS, Prescription Population, 2000-2015 40

Figure 21: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2015 41

Figure 22: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2015 42

Figure 23: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2015 45

Figure 24: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2015 46

Figure 25: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2015 47

Figure 26: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2015 50

Figure 27: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2015 51

Figure 28: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2015 52

Figure 29: MAbs Market, Global, Pipeline Segmentation by Disease, 2009 53

Figure 30: MAbs Market, Global, Oncology Pipeline, 2009 56

Figure 31: MAbs Market, Global, Autoimmune Diseases Pipeline, 2009 66

Figure 32: MAbs Market, Global, Respiratory Diseases Pipeline by Phase of Development, 2009 74

Figure 33: MAbs Market, Global, Infectious Diseases Pipeline by Phase of Development, 2009 76

Figure 34: MAbs Market, Global, Organ Transplantation Pipeline by Phase of Development, 2009 78

Figure 35: MAbs Market, Global, Cardiovascular Pipeline by Phase of Development, 2009 80

Figure 36: MAbs Market, Global, Other New Indications in Pipeline, 2009 82

Figure 37: MAbs Market, Global Major M&A Deals, 2008-2009 86

Figure 38: MAbs Market, Global, Major Licensing Agreements by Phase, 2008-2009 87

Figure 39: MAbs Market, Global, Major Licensing Agreements By Geography, 2008-2009 88

Figure 40: MAbs Market, Global, Major Licensing Agreements By Deal Value, 2008-2009 88

Figure 41: MAbs Market, Global, Top Three Companies, 2008 94

Figure 42: MAbs Market, Global, Top 5 Companies Sales Trend, 2006-2008 95

Figure 43: MAbs Market, Global, Key Target Therapies Launched, 1997-2009 96

Figure 44: MAbs Market, Global, Company Market Share Analysis, 2008 96

Figure 45: MAbs Market, Global, Company Benchmarking Analysis, 2008 97

Figure 46: MAbs Market, Global, Top 10 MAbs, 2006-2008 98

Figure 47: MAbs Market, Global, Roche/Genentech Revenue Segmentation, 2008 99

Figure 48: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015 100

Figure 49: MAbs Market, Global, Roche/Genentech R&D Pipeline by Therapeutic Area, November 2009 103

Figure 50: MAbs Market, Global, Roche/Genentech Pipeline Analysis by Phase, November 2009 104

Figure 51: MAbs Market, Global, Abbott Revenue Segmentation, 2008 104

Figure 52: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015 105

Figure 53: MAbs Market, Global, Abbott Pipeline Analysis by Phase, November 2009 106

Figure 54: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015 107

Figure 55: MAbs Market, Global, Johnson & Johnson R&D Pipeline by Therapeutic Area, November 2009 108

Figure 56: MAbs Market, Global, Johnson & Johnson Pipeline Analysis by Phase, November 2009 109

Figure 57: MAbs Market, Global, Biogen Idec Revenue Segmentation, 2008 109

Figure 58: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015 110

Figure 59: MAbs Market, Global, Biogen Idec R&D Pipeline by Therapeutic Area, November 2009 111

Figure 60: MAbs Market, Global, Biogen Idec Pipeline Analysis by Phase, November 2009 112

Figure 61: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015 113

Figure 62: MAbs Market, Global, Merck/Schering-Plough R&D Pipeline by Therapeutic Area, November 2009 114

Figure 63: MAbs Market, Global, Merck/Schering-Plough Pipeline Analysis by Phase, November 2009 114

Figure 64: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015 115

Figure 65: MAbs Market, Global, AstraZeneca R&D Pipeline by Therapeutic Area, November 2009 116

Figure 66: MAbs Market, Global, AstraZeneca Pipeline Analysis by Phase, November 2009 117

Figure 67: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015 118

Figure 68: MAbs Market, Global, Bristol-Myers Squibb R&D Pipeline by Phase, November 2009 119

Figure 69: MAbs Market, Global, Elan Revenues ($ m), 2006-2015 120

Figure 70: MAbs Market, Global, Elan R&D Pipeline by Therapeutic Area, November 2009 121

Figure 71: MAbs Market, Global, Elan Pipeline Analysis by Phase, November 2009 121

Figure 72: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015 122

Figure 73: MAbs Market, Global, Eli Lilly R&D Pipeline by Therapeutic Area, November 2009 123

Figure 74: MAbs Market, Global, Eli Lilly Pipeline Analysis by Phase, November 2009 124

Figure 75: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015 125

Figure 76: MAbs Market, Global, Amgen R&D Pipeline by Therapeutic Area, November 2009 127

Figure 77: MAbs Market, Global, Amgen Pipeline Analysis by Phase, November 2009 127

Figure 78: GBI Research Methodology 128

Figure 79: GBI Research Market Forecasting Model 131

To order this report:

Therapy Industry: The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds Peptic Ulcer Testing - A World Market Intelligence Report
2. Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
3. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
4. Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities
5. Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition)
6. Reportlinker Adds Childrens Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition
7. Reportlinker Adds Hand Sanitizers - US Market Trends
8. Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
9. Reportlinker Adds Imaging Agents - A Worldwide Market Review
10. Reportlinker Adds Toothpaste - Global Market Trends
11. Reportlinker Adds Cosmetic Surgery Procedures and Products - A US and European Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: